[A20-01] Dupilumab (atopic dermatitis in adolescents) - Addendum to Commission A19-75
Last updated 20.03.2020
Project no.:
A20-01
Commission:
Commission awarded on 06.01.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy
Result of dossier assessment:
Now hint (before: indication) of non-quantifiable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-75 | Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.